D3 Bio Reveals Promising Results for Elisrasib at ASCO 2026 in Untreated NSCLC#USA#Chicago#D3_Bio#elisrasib#ASCO_2026
D3 Bio Reveals Promising Results for Elisrasib at ASCO 2026 in Untreated NSCLC
D3 Bio announced impressive clinical data for Elisrasib, a KRAS G12C inhibitor, showing effective results in untreated NSCLC at ASCO 2026.
third-news.com
June 1, 2026 at 12:04 AM
D3 Bio Reveals Promising Results for Elisrasib at ASCO 2026 in Untreated NSCLC#USA#Chicago#D3_Bio#elisrasib#ASCO_2026
D3 Bio Unveils Promising KRAS Pipeline Results at AACR 2026 Conference in San Diego#USA#San_Diego#KRAS_G12C#D3_Bio#elisrasib
D3 Bio Unveils Promising KRAS Pipeline Results at AACR 2026 Conference in San Diego
D3 Bio shared impressive results for Elisrasib, a KRAS G12C inhibitor, during AACR 2026, highlighting its strong efficacy across various tumors.
third-news.com
April 30, 2026 at 3:25 AM
D3 Bio Unveils Promising KRAS Pipeline Results at AACR 2026 Conference in San Diego#USA#San_Diego#KRAS_G12C#D3_Bio#elisrasib
D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego#USA#San_Diego#oncology#D3_Bio#KRAS
D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego
D3 Bio Inc will present groundbreaking data on its KRAS pipeline at AACR 2026, highlighting innovative therapies for cancer treatments.
third-news.com
March 20, 2026 at 1:57 AM
D3 Bio Showcases Transformative KRAS Pipeline at AACR 2026 Meeting in San Diego#USA#San_Diego#oncology#D3_Bio#KRAS
D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications#Shanghai#USA#KRAS_G12D#D3_Bio#elisrasib
D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications
D3 Bio has received FDA clearance for two IND applications, paving the way for crucial cancer trials involving new therapeutics targeting KRAS mutations.
third-news.com
January 19, 2026 at 1:09 AM
D3 Bio Achieves FDA Clearance to Advance Innovative Cancer Trials with Two New IND Applications#Shanghai#USA#KRAS_G12D#D3_Bio#elisrasib
D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally#Shanghai#USA#D3_Bio#oncology_therapeutics#elisrasib
D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally
D3 Bio has successfully raised $108 million in Series B financing, aimed at enhancing their global oncology drug development initiatives and advancing their promising clinical programs.
third-news.com
December 10, 2025 at 1:40 AM
D3 Bio Raises $108 Million to Propel Oncology Therapeutics Forward Globally#Shanghai#USA#D3_Bio#oncology_therapeutics#elisrasib
D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers#Shanghai#United_States#KRAS_G12C#D3S-001#D3_Bio
D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers
D3 Bio, Inc. has announced that its drug D3S-001 has received FDA Breakthrough Therapy and Orphan Drug Designations for KRAS G12C-mutated cancers, highlighting its potential.
third-news.com
August 28, 2025 at 1:50 PM
D3 Bio's D3S-001 Receives Two Major FDA Designations for Treating KRAS G12C-Mutated Cancers#Shanghai#United_States#KRAS_G12C#D3S-001#D3_Bio